Mateos, M., Blacklock, H., Schjesvold, F., Oriol, A., Simpson, D., George, A., Goldschmidt, H., Larocca, A., Chanan-Khan, A., Sherbenou, D., Avivi, I., Benyamini, N., Iida, S., Matsumoto, M., Suzuki, K., Ribrag, V., Usmani, S. Z., Jagannath, S., Ocio, E. M., Rodriguez-Otero, P., San Miguel, J., Kher, U., Farooqui, M., Liao, J., Marinello, P., Lonial, S., & , (2019). pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet, 6(9), e459–e469. http://access.bl.uk/ark:/81055/vdc_100091258589.0x000009